First Flight has been preparing clients Camras Vision, Scion BioMedical and NIRvana Siences for presentations at the Southeast Bio Investing and Partnering Forum this week in Richmond, VA. Scion BioMedical will be presenting on the MAIN stage, while NIRvana and Camras will be featured on the Early Stage/Presenting Companies.
The Southeast BIO Investor & Partnering Forum is the Southeast region’s premier life sciences and medical technology conference, connecting emerging companies with potential investors and partners in a forum that provides meaningful networking opportunities. To date, over 350 biotechnology, medical device, pharmaceutical, diagnostic and healthcare IT companies from across the Southeast have presented at SEBIO’s annual Investor and Partnering Forum. These companies, in aggregate, have raised more than $2.5 billion in public and private funding since their presentations.
Camras Vision is an ophthalmic medical device company developing a patented new technology for the 67 million glaucoma sufferers. Ophthalmologists are faced with limited surgical treatments due to their instability and unpredictability in controlling glaucoma. As a result, 1 out of 10 patients still lose their vision even when properly treated. Camras Vision wishes to address these problems with their device, the Camras Shunt.
NIRvana Sciences is developing novel dyes that advance the field of multiplexing. NIRvana defines multiplexing as a type of test that simultaneously measures many color-labeled compounds in a single instrumentation run or test cycle. “This is a great opportunity for us to present our technology and gain wide exposure with potential investors and partners, ” indicates Russell Thomas, President of NIRvana.
Scion BioMedical is a leader in the development of solutions that are designed, engineered and manufactured to advance wound care, hemostasis and healing across the continuum of care. Our 100% proprietary Chitosan-based Polyprolate formulation is one of the most dynamic and effective solutions in the market today.